eli lilly glp-1 drugs US approves new oral weight-loss pill developed by | US news FDA approves new weight-loss pill,
Description
In a large Phase 3 clinical trial (STEP series), semaglutide demonstrated excellent weight loss and weight maintenance after weight loss
Conflict of interest The author has provided advisory services to AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, and Novo Nordisk, and has received lecture honoraria from Bristol Myers Squibb, Novartis and the above-mentioned companies
J Auton Nerv Syst
Exp Clin Endocrinol Amp Diabetes (2022) 130:35867
Yang, Y
[DOI] [PubMed] [Google Scholar] 513.Ozaki N., Shibasaki T., Kashima Y., Miki T., Takahashi K., Ueno H
